Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Shire Settles Litigation With Teva
Shire has settled the litigation with Teva over Shire’s supply to Teva of an authorised generic version of Adderall XR. Shire has been supplying Teva with authorised generic
Shire has settled the litigation with Teva over Shire’s supply to Teva of an authorised generic version of Adderall XR. Shire has been supplying Teva with authorised generic
TET Systems (TSH), the Academic Medical Center (AMC), and Technology Foundation STW have entered into an assignment agreement. Scientists at the AMC have previously developed a series of
Hana Biosciences has completed enrollment of its pivotal Phase 2 rALLy clinical trial for Marqibo (vincristine sulfate liposomes injection) for the treatment of adult acute lymphoblastic leukemia (ALL)
NanoBio has presented positive results from the studies in mice in which immune responses were evaluated following administration of 5µg doses of recombinant H5N1 flu antigen combined with
The Society of Chemical Manufacturers and Affiliates (SOCMA) has appointed Lawrence Sloan as president and CEO of the association, effective February 10, 2010. Sloan succeeds Joseph Acker, who
GSK has completed the extension of its strategic relationship with Aspen Pharmacare (Aspen) and the acquisition of a minority shareholding in the South African based pharmaceuticals company on
Pfizer and Protalix have entered into an agreement to develop and commercialise Taliglucerase Alfa, a plant-cell expressed form of glucocerebrosidase (GCD) in development for the potential treatment of
India-based Cipla is currently in talks with Pfizer with an intention to form strategic alliance, reported NDTV. The strategic alliance will focus on the needs of Pfizer in
Depomed has filed a lawsuit in the US District Court for the Northern District of California against Lupin and its wholly-owned subsidiary, Lupin Pharmaceuticals, for infringement of the
Jubilant Organosys, through its subsidiary Jubilant Biosys, has announced that its 4 year old research collaboration with Eli Lilly & Company, has successfully delivered multiple discovery milestones and